Portal de investigación
FI19/00153 (PFIS) CARLOS VILLARROEL (209/207): CONTRATOS PREDOCTORALES DE FORMACIÓN EN INVESTIGACIÓN EN SALUD. Acción Estratégica en Salud 2019.
Datos básicos
Documentos
- No hay documentos
Participantes
Grupos y Plataformas de I+D+i
Financiadores - Promotores
INSTITUTO SALUD CARLOS III
Resultados del Ensayo Clínico
Benzopyran hydrazones with dual PPARa/? or PPARa/d agonism and an anti-inflammatory effect on human THP-1 macrophages
García, A; (...); Cortes, D
Article. 10.1016/j.ejmech.2024.116125. 2024
Development of 2-and 3-prenylated quinolines and tetrahydroquinolines with PPAR activity: From hit to lead and a novel pan-PPAR agonist as a potential candidate for metabolic syndrome
Villarroel-Vicente, C; (...); Cabedo, N
Article. 10.1016/j.bioorg.2025.108450. 2025
Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: An overview.
Villarroel-Vicente, Carlos; (...); Cabedo, Nuria
Article. 10.1016/j.ejmech.2021.113535. 2021
Synthesis and biological studies of "Polycerasoidol" and "trans-d-Tocotrienolic acid" derivatives as PPARa and/or PPAR? agonists.
Vila, Laura; (...); Cortes, Diego
Article. 10.1016/j.bmc.2021.116532. 2022
Synthesis of 2-(3-aminopropyl)benzopyrans as potential antipsychotic agents targeting D2/D3 and 5-HT2A receptors
Bernabeu-Sanchis Á; (...); Cabedo N
Article. 10.1016/j.bmc.2025.118300. 2025
Synthesis of 2-aminopropyl benzopyran derivatives as potential agents against triple-negative breast cancer
García, A; (...); Cortes, D
Article. 10.1039/d3md00385j. 2023
Synthesis of 2-Prenylated Alkoxylated Benzopyrans by Horner-Wadsworth-Emmons Olefination with PPARa/? Agonist Activity.
Garcia, A; (...); Cortes, D
Article. 10.1021/acsmedchemlett.1c00400. 2021
Synthesis of a new 2-prenylated quinoline as potential drug for metabolic syndrome with pan-PPAR activity and anti-inflammatory effects
Villarroel-Vicente, C; (...); Cabedo, N
Article. 10.1016/j.bmcl.2024.129770. 2024
